rence of chronic diseases, such as cancer and autoimmune conditions,” noted Hans Straberg, chairman of Atlas Copco, and former CEO of Electrolux. “So Big Pharma and the industry are looking beyond the chemical and biologically derived molecules.” And as universities and small startups have taken the lead in R